Navigation Links
Sosei Signs Definitive Distribution Agreement With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Date:11/2/2009

TOKYO, November 2 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a definitive distribution agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo(R)).

NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo(R) contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse. NorLevo(R) was first launched in Europe in 1999 and is currently approved in some 60 countries, the product being both safe and effective as an oral emergency contraceptive for post-coital use.

Sosei have acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The NDA application for SOH-075 was submitted in Japan in September 2009.

The agreement is based on the terms of a binding letter of agreement that was announced on 22 October 2008. According to this agreement, Sosei is responsible for development and registration and ASKA for sales and marketing.

In accordance with the agreement, Sosei will receive upfront, milestone payments as well as a margin on product sales to ASKA.

Notes for Editors:

About Sosei

Sosei is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan. For further information about Sosei, please visit http://www.sosei.com.

SOURCE Sosei Group Corporation


'/>"/>
SOURCE Sosei Group Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sosei Announces Completion of Phase III Trial for NorLevo(R)
2. Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting
3. Sosei Confirms the Safety of SD118 in Two Phase I Trials
4. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
5. Sosei Assigns AD 923 Assets to Pharmasol
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
11. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- --> --> ... Spectroscopy Market by Industry (Oil & Gas, Petrochemical, Pharmaceutical, Water ... & Mining, and Others), And Geography - Global Forecast ... expected to grow to USD 3.9 Billion by 2020, ... 2020. Browse 82 market data Tables and ...
(Date:2/10/2016)... 10, 2016 A new report from business intelligence provider ... that the Alzheimer,s disease market will more than double from just under $5 ... Annual Growth Rate (CAGR) of 11%. Canada , ... , Spain , the UK, and Japan ... period. --> Canada , France , ...
(Date:2/10/2016)... SANFORD, Fla. , Feb. 10, 2016 ... offerings today with the launch of the Specialty Pharmacy ... is an industry-first, aimed at providing real-world education, discussion ... --> --> ... President and CEO of CSI Specialty Group Suzette DiMascio, ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... ... the World Molecular Imaging Congress (WMIC), will be held in New York City, ... is “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... known locally for a series of therapeutic sessions to help Los Angeles-area actors ... and in their lives. The series, known as “Mindfulness for Actors and Artists,” ...
(Date:2/10/2016)... NY (PRWEB) , ... February 10, 2016 , ... Early ... to celebrate and raise awareness of Nestlé KITKAT as the first global confectionery brand ... lives of cocoa farmers and the quality of their product, through activities that focus ...
(Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and ... in order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige ... Clio, only 15 miles away from Flint. , “We have deep roots in the ...
(Date:2/10/2016)... PLAINSBORO, N.J. (PRWEB) , ... ... ... J. Hennessy Associates, Inc. , a full-service health care communications company offering ... integrated digital news resource for practitioners and specialists working in infectious diseases. ...
Breaking Medicine News(10 mins):